VEGFR-3和CD_(31)在前列腺癌中的表达及其与生存率的关系  

The correlation between the expression of VEGFR-3,CD31 and survival rate in prostate cancer

作　　者：徐银峰[1] 丁国芳[1] 方海飞[1] 郁迪[1] 闫海强[1] 李继承[2] 

机构地区：[1]浙江海洋学院医学院,舟山316004 [2]浙江大学细胞生物学研究所

出　　处：《中华泌尿外科杂志》2006年第S2期47-49,共3页Chinese Journal of Urology

基　　金：浙江省自然科研基金资助项目(Y205519);浙江省教育厅科研基金资助项目(20040540);浙江海洋学院科研基金资助项目(X05LY13)

摘　　要：目的探讨VEGFR-3和CD31在前列腺癌组织的表达及与术后生存率关系。方法采用EnVisionTM免疫组织化学法,检测43例前列腺癌癌组织和10例癌周组织VEGFR-3和CD31表达,采用Weidner最高血管密度计数法,计数癌组织中阳性淋巴管数(MLC)和微血管密度(MVD);结合临床资料分析VEGFR-3和CD31与前列腺癌术后生存率的关系。结果前列腺癌组织中MLC和MVD分别为(8.90±2.28)mm2和(72.46±10.32)mm2,显著高于癌周组织的(4.03±2.16)mm2和(30.91±5.27)mm2,差异有统计学意义(P【0.01)。术后2年内死亡者的MLC和MVD分别为(10.52±1.83)mm2与(92.30±10.19)mm2;2~5年死亡者分别为(8.59±2.73)mm2和(85.87±12.95)mm2;】5年死亡者分别为(6.67±1.23)mm2与(61.19±10.50)mm2,差异有统计学意义(P【0.05)。TNM分期T1、T2期者MLC和MVD分别(7.46±1.13)mm2与(65.10±12.84)mm2,T3、T4期者分别为(9.25±2.51)mm2与(83.78±10.83)mm2,差异有统计学意义(P【0.05)。无骨转移者(72.09%)MLC和MVD分别为(6.67±1.23)mm2与(61.19±10.50)mm2;有骨转移者(27.91%)分别为(10.37±1.06)mm2与(97.74±14.62)mm2,差异有统计学意义(P【0.05)。结论VEGFR-3和CD31高表达提示前列腺癌组织有新淋巴管和血管生成,VEGFR-3和CD31检测可用于判断前列腺癌患者的生存质量。Objective To study the correlation between the expression of VEGFR-3 and CD31 in prostate cancer tissues and survival rate after operation,which can be use to estimate and prognosis. Methods Using EnVisionTM immunohistochemical method,43 specimens of prostate cancer tissue after operation and 10 adjacent nontumorous tissue specimens were tested for the expression of VEGFR-3 and CD31. They were marked by VEGFR-3 and CD31 with immunohistochemistic staining and analyzed with image ,the micro-lymphatics count (MLC) and microvessel density (MVD) were counted using Weidner's highest vessel density count method. The correlation between VEGFR-3 and CD31 and survival rate after operation was analytion. Results The MLC and MVD were (8.90±2.28)mm2,(72.46±10.32)mm2 significantly higher than those in adjacent nontumorous tissue (MLC, 4.03±2.16/mm2; MVD, 30.91 5.27/mm2) (P<0.01) in prostate cancer. The MLC and MVD in those who died in 2 year were (10.52 1.83)mm2 and (92.30±10.19)mm2, in those who died in 2~5 year were (8.59±2.73)mm2 and (85.87 12.95)mm2, in those who died in after 5 year were (6.67±1.23)mm2 and (61.19±10.50)mm2, respectively which indication significant difference between them(P<0.05). As TNM grading was Ⅰ,Ⅱ,the MLC and MVD were (7.46±1.13)mm2 and (65.10±12.84)mm2, as TNM grading wasⅢ, Ⅳ, the MLC and MVD were (7.46±1.13)mm2 and (83.78±10.83)mm2, indicating significant difference between them(P<0.05). The MLC and MVD in those(72.09%) who have no bone metastasis were (6.67±1.23)mm2 and (69.19±10.50)mm2,while they were (10.37±1.06)mm2 and (97.74±14.62)mm2 in those(27.91%) who have bone metastasis, indicating significant difference between them(P<0.05).The fact imdicating that higher the MLC and MVD expression of VEGFR-3 and CD31 were, stronger the metastasis dose,lower the patients survival rate was and higher the patients rate of dead was. Conclusions VEGFR-3 and CD31 could accelerate the hyperplasia of micro-lymphatics and neoangiogenesis induced by tumor and play an important role in tum

关 键 词：前列腺肿瘤 癌 血管内皮生长因子受体-3 CD₃₁ 生存率 

分 类 号：R737.25[医药卫生—肿瘤]